Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Give the vial 35 minutes of rest
ACT-AD Phase 2 Trial Fosgonimeton's Phase 2 ACT-AD trial in Alzheimer's patients fails its primary endpoint
Reduces oxidative damage to cells and DNA, which is a primary driver of visible aging and tissue degradation
I am not passionate about research to only develop treatments, as that itself can oftentimes perpetuate ableist messaging, but I want to conduct translational research that gives patients more options than there is no cure. Thanks to UMichs commitment to expanding research opportunities, I was able to find a research project in my first semester investigating goals for end-of-life care for patients with Alzheimers and Dementia
Individuals with metabolic imbalance, chronic inflammation or slower healing linked to lifestyle or metabolic factors
US$ 28.56
US$ 22.96
US$ 26.30
US$ 24.83
